Mammographic density as a biosensor of tamoxifen effectiveness in adjuvant endocrine treatment of breast cancer: Opportunities and implications

Maeve Mullooly, Ruth M. Pfeiffer, Sarah J. Nyante, Brandy M. Heckman-Stoddard, Marjorie Perloff, Ismail Jatoi, Louise A. Brinton, Erin J.Aiello Bowles, Robert N. Hoover, Andrew Glass, Amy Berrington De Gonzalez, Mark E. Sherman, Gretchen L. Gierach

Research output: Contribution to journalArticle

8 Scopus citations
Original languageEnglish (US)
Pages (from-to)2093-2097
Number of pages5
JournalJournal of Clinical Oncology
Volume34
Issue number18
DOIs
StatePublished - Jun 20 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Mullooly, M., Pfeiffer, R. M., Nyante, S. J., Heckman-Stoddard, B. M., Perloff, M., Jatoi, I., Brinton, L. A., Bowles, E. J. A., Hoover, R. N., Glass, A., De Gonzalez, A. B., Sherman, M. E., & Gierach, G. L. (2016). Mammographic density as a biosensor of tamoxifen effectiveness in adjuvant endocrine treatment of breast cancer: Opportunities and implications. Journal of Clinical Oncology, 34(18), 2093-2097. https://doi.org/10.1200/JCO.2015.64.4492